Horizon Europe · Europäische Union

Innovative healthcare interventions for non-communicable diseases

Offen

Das EU-Programm Horizon Europe plant 8 Förderungen mit 7 Mio. € – 8 Mio. € pro Projekt bei einem Gesamtbudget von 63,8 Mio. €. Die Einreichungsfrist endet am 17. Februar 2027 (EU-Ausschreibungen enden meist um 17:00 Uhr Brüsseler Zeit). Organisationen aus EU-Mitgliedstaaten und assoziierten Ländern wie der Türkei können in der Regel teilnehmen; maßgeblich sind die Bedingungen des Topics.

Frist: 17. Februar 2027 (in 94 Tagen)
Fördersumme: 7 Mio. € – 8 Mio. € pro Projekt
Gesamtbudget: 63,8 Mio. €
Förderquote: 100 % der förderfähigen Kosten Standardregel des Programms; die Ausschreibung kann abweichen.
Gesamtbudget: 63,8 Mio. €
Erwartete Förderungen: 8
Maßnahmentyp: HORIZON Research and Innovation Actions · HORIZON Lump Sum Grant
Wahrscheinliche Antragstellende: Unternehmen, KMU / Start-ups, Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber: Horizon Europe (HORIZON)
Referenz: HORIZON-HLTH-2027-02-DISEASE-01-two-stage
Ausschreibung: HORIZON-HLTH-2027-02-two-stage
Zuletzt geprüft: 14. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Erwartete Ergebnisse

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Researchers, developers and clinical practitioners have access to state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to develop innovative healthcare interventions aimed at reducing burden of the following specific Non-Communicable Diseases (NCDs): cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases.

• Scientific and clinical communities can use innovative healthcare interventions to generate meaningful advances in clinical practice and care for patients with NCDs following validation in late-stage clinical trials.

Vollständigen Text lesen

• Scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR [1] principles, thereby encouraging further use of the data.

• Policymakers, scientific and clinical communities, developers, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.

• Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.

Umfang

NCDs represent over 80% of the disease burden in Europe and the leading cause of avoidable premature deaths. Innovative and effective healthcare interventions are required to provide treatment and disease management solutions and assure best quality of care for patients suffering from NCDs when prevention strategies have failed.

Proposals should address all the following aspects:

• Perform rigorous early stage [2] clinical trial(s) to validate novel or refined healthcare interventions [3] for treatment and/or disease management solutions for patients suffering from the following specific NCDs: cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases [4] . Whenever relevant, existing co- and multimorbidities should be addressed in the trial design.

• Clinical trial(s) should be supported by completed proof-of-concept [5] of clinical safety and efficacy.

• Both preclinical research and the draft clinical trial protocol should be completed at the time of submission of the proposal. Proposals should also demonstrate evidence of preliminary consultations with ethics and regulatory authorities at the time of submission.

Vollständigen Text lesen

• A sound feasibility assessment, including an appropriate patient selection and realistic recruitment plans, justified by publications or preliminary results should be provided.

• Take into account sex and gender differences in all relevant aspects throughout the research process, and consider stratification criteria such as age, disability, racial or ethnic origin [6] , socio-economic status, genetic and epigenetic variations, etc., where relevant.

• Use and/or develop technologies, including digital ones (e.g. (generative) Artificial Intelligence, wearable technologies) to help implement and monitor the long-term efficacy of the intervention(s), as well as manage the disease and/or monitor their progression (e.g. with unobtrusive technologies suitable for patient monitoring at home and in real-world conditions), whilst also ensuring they are bias-free, inclusive, and ethically sound. Hardware and software should be interoperable in line with internationally accepted standards [7] . The use of virtual human twins [8] could also be considered, where relevant.

• Exploit existing data, health data infrastructures [9] , biobanks, registries and/or cohorts, together with the generation of new data that should be managed in line with the FAIR principles and contribute to emerging research infrastructures established in the framework of the European Health Data Space (EHDS) [10] , when relevant.

• Advance research by leveraging already existing and emerging state-of-the-art research infrastructures as well as results stemming from EU-supported research projects, where applicable.

• Engage all relevant stakeholders (especially patients and patients’ representatives, caregivers, clinicians, counsellors, regulators, etc.) to design end-user optimised interventions.

• Engage with national public health…

Wer kann sich bewerben?

Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Cardiac and Cardiovascular systems Clinical medicine Clinical research Clinical trials Nephrology Peripheral vascular disease Respiratory systems Type 1 diabetes Type 2 diabetes Innovative interventions NCD non-communicable diseases

Zeitplan

Two-stage call. Next deadline 2027-02-17; later stage/cut-off 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).

So bewerben Sie sich

Lesen Sie das vollständige Topic im Portal: erwartete Ergebnisse, Umfang, Maßnahmentyp und die Teilnahmebedingungen einschließlich Länder- oder Konsortialvorgaben.
Registrieren Sie jede Partnerorganisation im EU Funding & Tenders Portal, um einen PIC zu erhalten.
Verbundprojekte in Forschung und Innovation benötigen in der Regel mindestens drei unabhängige Partner aus drei verschiedenen EU-Mitgliedstaaten oder assoziierten Ländern. Prüfen Sie die Regel für dieses Topic.
Bereiten Sie Teil A (Verwaltungsformulare und Budget im Portal) und Teil B (technische Beschreibung auf der offiziellen Vorlage für diesen Maßnahmentyp) vor.
Reichen Sie vor dem Fristende am Stichtag im Portal ein. Verspätete Anträge werden nicht angenommen.

From the call text

Who can apply: Not stated in the call text we hold — check the official page
Company stage: Not stated in the call text we hold — check the official page
Single applicant or consortium: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where applicants must be based: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where to apply: Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.

EU-Leitfaden zur Antragstellung lesen

Offizielle Quellen

Offizielle Ausschreibungsseite

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 14. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.